

ELITE PHARMACEUTICALS INC /DE/  
Form 8-K  
September 30, 2009

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**September 24, 2009**

-----  
Date of Report (Date of earliest event reported)

**ELITE PHARMACEUTICALS INC.**

-----  
(Exact name of registrant as specified in its charter)

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-15697**

(Commission  
File Number)

**22-3542636**

(IRS Employer  
Identification No.)

165 Ludlow Avenue, Northvale NJ 07647

-----

(Address of principal executive offices)

(201) 750-2646

-----

(Company's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On September 24, 2009 Dr. Melvin H. Van Woert resigned from the board of directors of Elite Pharmaceuticals, Inc.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

September 30, 2009

**ELITE PHARMACEUTICALS, INC.**

By: /s/ Chris Dick  
Chris Dick  
President and Chief Operating Officer

---